Literature DB >> 12455037

The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda.

Robert Newton1, John Ziegler, Dimitra Bourboulia, Delphine Casabonne, Valerie Beral, Edward Mbidde, Lucy Carpenter, Gillian Reeves, D Maxwell Parkin, Henry Wabinga, Sam Mbulaiteye, Harold Jaffe, Robin Weiss, Chris Boshoff.   

Abstract

The association between the prevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV or human herpesvirus 8 [HHV-8]) and sociodemographic, sexual, reproductive and lifestyle factors was investigated in a study of adults presenting with cancer at hospitals in Kampala, Uganda. Patients were interviewed and tested for antibodies against KSHV (using an indirect immunofluorescent assay). Data are presented for 607 patients who were not infected with the human immunodeficiency virus-1 (HIV) and who did not have Kaposi's sarcoma (these included people with cancers of the uterine cervix [140], breast [58], liver [41], oesophagus [36], lymphoma [47], other cancers [285] and benign tumours [63]). The prevalence of anti-KSHV antibodies was 50% overall (302/607) and did not differ significantly by cancer site (p = 0.4) or sex (p = 0.2), but increased linearly with age from 35% in those under 25 years to 55% in those 45 years and over (chi(2) trend [1 df] = 9.1; p < 0.001). After adjusting for age and sex, anti-KSHV antibodies were more common in tribal groups other than the Baganda tribe (54% vs. 45% among Baganda; p = 0.02), but there was no significant (p > 0.05) variation in seroprevalence by district of birth, region of residence prior to becoming ill or various measures of wealth. The prevalence of anti-KSHV antibodies decreased with increasing number of older siblings, although this may be due to chance (p = 0.05) and was higher among people who had ever been married (p = 0.03). There was no significant association (p > 0.05) between the presence of antibodies against KSHV and other sexual and reproductive factors. Among the 302 patients with anti-KSHV antibodies, the proportion with high titres increased linearly with increasing age (p = 0.03) and was higher among those reporting having had a blood transfusion (p = 0.03). In conclusion, in this population in Uganda, where KSHV is relatively common, the prevalence of anti-KSHV antibodies increased with age but showed little association with nearly 50 other factors studied. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12455037     DOI: 10.1002/ijc.10817

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

Authors:  Eliane Rohner; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Helena Rabie; Daniela Garone; Diana Dickinson; Cleophas Chimbetete; Priscilla Lumano-Mulenga; Izukanji Sikazwe; Natascha Wyss; Kerri M Clough-Gorr; Matthias Egger; Benjamin H Chi; Julia Bohlius
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

2.  HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data.

Authors:  Sam M Mbulaiteye; Kishor Bhatia; Clement Adebamowo; Annie J Sasco
Journal:  Infect Agent Cancer       Date:  2011-10-17       Impact factor: 2.965

3.  Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt".

Authors:  Sheila C Dollard; Lisa M Butler; Alison M Graves Jones; Jonathan H Mermin; Midion Chidzonga; Tsungai Chipato; Caroline H Shiboski; Christian Brander; Anisa Mosam; Photini Kiepiela; Wolfgang Hladik; Jeffrey N Martin
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

4.  Kaposi Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008.

Authors:  Robert Newton; Nazzarena Labo; Katie Wakeham; Wendell Miley; Gershim Asiki; W Thomas Johnston; Denise Whitby
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

5.  Relationship between viral factors, axillary lymph node status and survival in breast cancer.

Authors:  Ju-Hsin Tsai; Chun-Sen Hsu; Chung-Hung Tsai; Jang-Ming Su; Yin-Tso Liu; Min-Hsiung Cheng; James Cheng-Chung Wei; Fong-Lin Chen; Chi-Chiang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-25       Impact factor: 4.553

6.  Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily.

Authors:  Colleen Pelser; Francesco Vitale; Denise Whitby; Barry I Graubard; Angelo Messina; Lorenzo Gafà; Elizabeth E Brown; Lesley A Anderson; Nino Romano; Carmela Lauria; James J Goedert
Journal:  J Med Virol       Date:  2009-11       Impact factor: 2.327

7.  Risk factors for early childhood infection of human herpesvirus-8 in Zambian children: the role of early childhood feeding practices.

Authors:  Kay L Crabtree; Janet M Wojcicki; Veenu Minhas; David R Smith; Chipepo Kankasa; Charles D Mitchell; Charles Wood
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-02       Impact factor: 4.254

8.  Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe.

Authors:  Thomas B Campbell; Margaret Borok; Buxton Ndemera; Suzanne Fiorillo; Irene E White; Xing-quan Zhang; Rhoderick N Machekano; David Katzenstein; Lovemore Gwanzura
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

9.  Human herpesvirus-8 infection and oral shedding in Amerindian and non-Amerindian populations in the Brazilian Amazon region.

Authors:  Vanda A U F de Souza; Laura M Sumita; Maria-Claudia Nascimento; Juliane Oliveira; Melissa Mascheretti; Mariana Quiroga; Wilton S Freire; Adriana Tateno; Marcos Boulos; Philippe Mayaud; Claudio S Pannuti
Journal:  J Infect Dis       Date:  2007-08-06       Impact factor: 5.226

10.  Infection and cervical neoplasia: facts and fiction.

Authors:  Wael I Al-Daraji; John Hf Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.